Company webinar

Dimerix (ASX:DXB)

Watch our webinar with Dimerix, featuring Managing Director Dr Nina Webster. An interview followed by live Q&A with the audience.

Date
September 21, 2026
Time
Where
Online
Entry
Free
Dr Nina Webster
Dr Nina Webster
Managing Director, Dimerix (ASX:DXB)

About the company

Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company developing new therapies for kidney diseases with significant unmet medical need. The Company’s lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, Dimerix is advancing a Phase 2 program with DMX-652 in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications.

Key topics

  • The global opportunity in kidney disease
  • The Phase3 ACTION3 clinical trial for DMX-200 - overview and upcoming inflection points
  • Dimerix’s commercial licensing partners, with 5 partners secured (collectively valued up to $1.9 billion in upfront and potential milestone payments + royalties on net sales)
  • The newly acquired DMX-652 and how this supports the company’s strategic goal of expanding its renal pipeline
  • The DMX-652 Phase 2 trial - overview and upcoming inflection points
  • The competitive landscape for both DMX-200 and DMX-652
  • The company’s IP strategy
  • Key upcoming milestones for investors

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →